ArticleCancer science2026
The Role of IGF2BP3-Mediated Immune Response Activation in Enhancing Immunotherapy of Koumine for Gastric Cancer.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Resistance to immune checkpoint blockade in gastric cancer often arises from defective antigen presentation due to MHC-I downregulation, yet strategies to restore MHC-I expression remain limited. Here, using the natural alkaloid koumine as a chemical probe, we identified IGF2BP3 as a druggable regulator of MHC-I antigen presentation. Network pharmacology, proteomics, surface plasmon resonance, and cellular thermal shift assays were used to identify and validate koumine's target. Genetic rescue experiments, loss-of-function studies, in vitro T-cell co-culture assays, and in vivo gastric cancer mouse models were performed to confirm the causal relationship. m6A-seq and ChIP-seq analyses delineated the downstream epigenetic pathway. Koumine binds IGF2BP3 and promotes its proteasome-dependent degradation, which reduces m6A enrichment on EED mRNA, accelerates EED decay, lowers H3K27me3, and derepresses IRF transcription, thereby restoring MHC-I expression and enhancing CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.